Epiphany Biosciences Discovers $36M
San Francisco-based Epiphany Biosciences has scored $36M in a Series A funding round, the firm said this week. Epiphany Biosciences said that it has a therapeutic focus on discovering and developing anti-infective agents. The firm's funding was led by Wexford Capital, and also included Windsor Bay Capital, Global Trust Ventures Management, and CDIB BioScience Venture Management and other investors. Epiphany's lead candidate is an anti-viral targeted against shingles.
posted on Friday, March 16, 2007 (Link to more information)
Related companies:
Epiphany
Related stories:
> 3-V Biosciences Finds $20M In Funding
> Pacific Biosciences Raises $50M
> Imago Biosciences Sees $26.5M
> Annexon Biosciences Gets $44M
> Flexus Biosciences Acquired For $1.25 Billion
silicontap.com Home